{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:06:28Z","timestamp":1779955588374,"version":"3.53.1"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Psoriatic arthritis (PsA) outcomes have improved, yet many patients do not achieve sustained control, and a meaningful proportion develop difficult-to-treat disease. This review summarizes relevant new therapies in the PsA pipeline and highlights emerging strategies likely to shape near-term care, including interception, metabolic targeting, combination\/sequence approaches, and early precision-medicine efforts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Pipeline innovation clusters in three areas: interleukin (IL)-17 pathway advances, including dual IL-17A\/IL-17F blockade and engineered formats (nanobodies\/small scaffolds) that may alter tissue pharmacology; selective tyrosine kinase 2 inhibition (allosteric and highly selective catalytic-site inhibitors) expanding oral options; and oral IL-23 receptor antagonism progressing from strong psoriasis efficacy into phase 3 PsA development. Beyond new molecules, strategies are evolving. Exploratory evidence supports further evaluation of dual-targeted approaches for highly refractory PsA, while metabolic targeting with incretin-based therapy is being tested as an adjunct to immunomodulation to address obesity-linked inflammatory amplification and cardiometabolic risk. EULAR transition frameworks, prodromal musculoskeletal symptoms and imaging abnormalities support a plausible interception window in at risk psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The next wave in PsA will be defined by both new agents and smarter strategies: more oral\/selective therapies, testing interception in risk-enriched psoriasis, integrating metabolic approaches, and evaluating optimized sequencing and selected combination therapy while precision tools mature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001157","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:01:08Z","timestamp":1773752468000},"page":"215-224","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["What's next in psoriatic arthritis therapy? A look at the pipeline"],"prefix":"10.1097","volume":"38","author":[{"given":"Enrique R.","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"R1-20260528","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20260528","doi-asserted-by":"crossref","first-page":"159","DOI":"10.46497\/ArchRheumatol.2024.10710","article-title":"Unmet needs in psoriatic arthritis, a narrative review","volume":"39","author":"Lopez-Medina","year":"2024","journal-title":"Arch Rheumatol"},{"key":"R3-20260528","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ard.2025.10.002","article-title":"EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis","volume":"85","author":"Marzo-Ortega","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R4-20260528","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41584-025-01329-3","article-title":"Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative","volume":"22","author":"Proft","year":"2026","journal-title":"Nat Rev Rheumatol"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"487","DOI":"10.36849\/JDD.2020.4957","article-title":"Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes","volume":"19","author":"Blauvelt","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"R6-20260528","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40674-019-00135-9","article-title":"Interventions on modifiable risk factors for the development of psoriatic arthritis","volume":"5","author":"Soriano","year":"2019","journal-title":"Curr Treat Options Rheumatol"},{"key":"R8-20260528","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jaad.2020.08.060","article-title":"Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational studies","volume":"84","author":"Xie","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R9-20260528","doi-asserted-by":"crossref","first-page":"e004314","DOI":"10.1136\/rmdopen-2024-004314","article-title":"Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage","volume":"10","author":"Zabotti","year":"2024","journal-title":"RMD Open"},{"key":"R10-20260528","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R11-20260528","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11926-020-00891-x","article-title":"From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention","volume":"22","author":"Zabotti","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"R13-20260528","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.det.2024.02.014","article-title":"Prevention of psoriatic arthritis: the need for prospective studies","volume":"42","author":"Wu","year":"2024","journal-title":"Dermatol Clin"},{"key":"R14-20260528","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/annrheumdis-2021-221255","article-title":"Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free?","volume":"81","author":"McGonagle","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R15-20260528","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Acosta Felquer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R16-20260528","doi-asserted-by":"crossref","first-page":"105833","DOI":"10.1016\/j.jbspin.2024.105833","article-title":"Early methotrexate treatment for psoriatic arthritis prevention in psoriasis patients \u2013 a retrospective cohort study","volume":"92","author":"Bar","year":"2025","journal-title":"Joint Bone Spine"},{"key":"R17-20260528","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R18-20260528","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40744-024-00680-3","article-title":"From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis","volume":"11","author":"Watad","year":"2024","journal-title":"Rheumatol Ther"},{"key":"R19-20260528","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","article-title":"Does biologic therapy impact the development of PsA among patients with psoriasis?","volume":"81","author":"Meer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R20-20260528","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40259-024-00689-8","article-title":"Effect of biological therapy for psoriasis on the development of psoriatic arthritis: a population-based cohort study","volume":"39","author":"Cho","year":"2025","journal-title":"BioDrugs"},{"key":"R21-20260528","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ard.2025.01.006","article-title":"Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics","volume":"84","author":"Gisondi","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R22-20260528","doi-asserted-by":"crossref","first-page":"AB1","DOI":"10.1016\/j.jaad.2023.07.016","article-title":"42744 do biologics for psoriasis prevent the development of psoriatic arthritis? A population-based study","volume":"89","author":"Miao","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R23-20260528","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"R24-20260528","doi-asserted-by":"crossref","first-page":"e063650","DOI":"10.1136\/bmjopen-2022-063650","article-title":"Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial","volume":"12","author":"Haberman","year":"2022","journal-title":"BMJ Open"},{"key":"R25-20260528","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40744-024-00708-8","article-title":"Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies","volume":"11","author":"Mease","year":"2024","journal-title":"Rheumatol Ther"},{"key":"R26-20260528","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"R27-20260528","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1038\/s41591-025-03971-6","article-title":"Sonelokimab, an IL-17A\/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial","volume":"31","author":"McInnes","year":"2025","journal-title":"Nat Med"},{"key":"R28-20260528","doi-asserted-by":"crossref","first-page":"18102","DOI":"10.1038\/s41598-022-23152-6","article-title":"A novel anti-TNF-\u03b1 drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis","volume":"12","author":"Oyama","year":"2022","journal-title":"Sci Rep"},{"key":"R29-20260528","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ard.2025.02.019","article-title":"Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"84","author":"Taylor","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R30-20260528","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ard.2025.05.388","article-title":"LB0001 Efficacy and safety of deucravacitinib up to week 16 from POETYK PSA-1: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with active psoriatic arthritis","volume":"84","author":"van der Heijde","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R31-20260528","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ard.2025.05.117","article-title":"OP0095 Efficacy and safety of deucravacitinib up to week 52 from POETYK PsA-2: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with psoriatic arthritis","volume":"84","author":"Mease","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R32-20260528","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jdv.20553","article-title":"Deucravacitinib in plaque psoriasis: four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials","volume":"39","author":"Armstrong","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R33-20260528","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R34-20260528","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ard.2025.05.023","article-title":"Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study","volume":"84","author":"Kivitz","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R35-20260528","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R36-20260528","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa2504187","article-title":"Oral icotrokinra for plaque psoriasis in adults and adolescents","volume":"393","author":"Bissonnette","year":"2025","journal-title":"N Engl J Med"},{"key":"R39-20260528","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R40-20260528","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"key":"R41-20260528","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b2 blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R42-20260528","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study","volume":"27","author":"Ahern","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R43-20260528","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R44-20260528","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"R47-20260528","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamadermatol.2025.2980","article-title":"Comparative risk of infection and prevalence of combination targeted therapy in psoriatic arthritis","volume":"161","author":"Wu","year":"2025","journal-title":"JAMA Dermatol"},{"key":"R48-20260528","doi-asserted-by":"crossref","first-page":"1283251","DOI":"10.3389\/fimmu.2023.1283251","article-title":"Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain","volume":"14","author":"Valero-Martinez","year":"2023","journal-title":"Front Immunol"},{"issue":"Suppl 9","key":"R49-20260528","first-page":"1082","article-title":"Combination of biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: a case-series [abstract]","volume":"77","author":"Lucas Ribeiro","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R50-20260528","doi-asserted-by":"crossref","first-page":"103865","DOI":"10.1016\/j.autrev.2025.103865","article-title":"Combination targeted therapy with two biologic\/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy","volume":"24","author":"Lignou","year":"2025","journal-title":"Autoimmun Rev"},{"key":"R52-20260528","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1136\/annrheumdis-2022-222415","article-title":"Sequential interleukin-17\/interleukin-23 inhibition in treatment-refractory psoriatic arthritis","volume":"81","author":"Simon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R53-20260528","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40744-022-00514-0","article-title":"Sequencing of biologic and target synthetic disease-modifying anti-rheumatic drugs in psoriatic arthritis: are we ready to redefine the treatment strategy? A perspective","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatol Ther"},{"key":"R54-20260528","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3899\/jrheum.121162","article-title":"Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis","volume":"40","author":"Chandran","year":"2013","journal-title":"J Rheumatol"},{"key":"R55-20260528","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/23808993.2020.1724509","article-title":"Predicting therapeutic response through biomarker analysis in psoriatic arthritis, an example of precision medicine","volume":"5","author":"Chandran","year":"2020","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"R56-20260528","doi-asserted-by":"crossref","first-page":"108318","DOI":"10.1016\/j.clim.2019.108318","article-title":"Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: a review of literature","volume":"211","author":"Pouw","year":"2020","journal-title":"Clin Immunol"},{"key":"R57-20260528","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jaad.2024.06.106","article-title":"Risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics: a population-based analysis","volume":"91","author":"Strober","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"R58-20260528","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40259-025-00705-5","article-title":"Interleukin-23 versus interleukin-17 inhibitors in preventing incidental psoriatic arthritis in patients with psoriasis: a real-world comparison From the TriNetX US Collaborative Network","volume":"39","author":"Yu","year":"2025","journal-title":"BioDrugs"},{"key":"R59-20260528","doi-asserted-by":"crossref","first-page":"keaf489","DOI":"10.1093\/rheumatology\/keaf489","article-title":"Psoriatic arthritis risk in psoriasis patients receiving anti-IL-23 vs. anti-IL-17: comparison of drug classes and individual agents","volume":"65","author":"Lin","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"R60-20260528","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/rheumatology\/keae257","article-title":"Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development","volume":"64","author":"Floris","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R61-20260528","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.41946","article-title":"Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study","volume":"74","author":"Rosenthal","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R62-20260528","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1093\/rheumatology\/keaf364","article-title":"TNF-alpha inhibitors reduce the incidence of PsA in patients with psoriasis: a propensity score-matched cohort study","volume":"64","author":"Piaserico","year":"2025","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:01:14Z","timestamp":1779955274000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001157","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}